Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESO-Shanghai9: Extensive Field Postoperative Chemoradiotherapy for ESCC
NCT02916511Phase 2Completed
- Sponsor
- Fudan University
- Start
- Sep 2016
- Primary completion
- Jul 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Primary endpoints: Local Control Rate at 2 years and Safety at 2 years. Started Sep 2016; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02916511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916511.